Briefing
Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.
Phased variants had a lower background rate than SNVs, including duplex SNVs (1.2e-6 vs 3.8e-5 and 1.0e-5). PhasED-Seq detected all 5 SNV-positive samples and 5 additional samples at tumor fractions as low as 0.000094%. In one patient with stage III adenocarcinoma, PhasED-Seq detected MRD in three on-treatment samples that were undetectable by SNVs, including a sample 8 months before progression.
- n: Personalized PhasED-Seq applied in 5 patients with localized NSCLC (14 plasma samples); methodologic series
- Assay: PhasED-Seq (personalized phased-variant sequencing after tumor/normal whole-genome sequencing)